20 September 2022
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified that Dr Adrian Kinkaid, CEO, has today purchased 4,000 ordinary shares of 4 pence each in the Company ("Ordinary Shares") at a price of 53.9p per share. Following this purchase, Dr Kinkaid holds 4,000 Ordinary Shares, representing approimately 0.02% of the Company's total issued share capital.
The following notification, made in accordance with the requirements of the UK Market Abuse Regulation, gives further details.
Details of the person discharging managerial responsibilities / person closely associated
Dr Adrian Kinkaid
Reason for the notification
Chief Executive Officer
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Fusion Antibodies plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary shares of 4p each in Fusion Antibodies plc
Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16
Nature of the transaction
Purchase of shares
Price(s) and volume(s)
- Aggregated volume
Date of the transaction
20 September 2022
Place of the transaction
London Stock Exchange, XLON
Fusion Antibodies plc
Dr Adrian Kinkaid, Chief Executive Officer
James Fair, Chief Financial Officer
Via Walbrook PR
Allenby Capital Limited
Tel: +44 (0)20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke (Sales and Corporate Broking)
Tel: +44 (0)20 7933 8780 or [email protected]
Mob: +44 (0)7876 741 001
Mob: +44 (0)7980 541 893
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.